ADC Learning Center

Embark on an exhilarating journey into the forefront of cancer treatment with our cutting-edge learning center curated by top-tier oncologists specializing in antibody-drug conjugates (ADCs). Tailored exclusively for community oncologists and care teams, this immersive experience delves deep into the intricate world of ADCs in clinical practice. Explore the latest advancements, mechanisms, and clinical applications of ADCs, as our expert panel unravels the secrets of this transformative therapy. Our mission? To turbocharge your clinical proficiency, empowering you to skillfully navigate the nuances of ADCs within a comprehensive educational environment. Get ready to revolutionize patient care and elevate survival outcomes – because the future of oncology starts here!

LikeLikedUnlike

Episodes 1-15 of 20

MinuteCE®
Triple-Negative Breast Cancer (TNBC): Choosing the Right ADC for the Right Patient
- Sara A. Hurvitz, MD, FACP
  Peer
- Sara M. Tolaney MD, MPH
  Peer
1.00 credits 9 episodes
MinuteCE®
Expanding ADCs Across Metastatic Breast Cancer: Disrupting Dx & Tx Silos
- Erica L. Mayer, MD, MPH
  Peer
- Sarah Sammons, MD
  Peer
1.00 credits 9 episodes
MinuteCE®
Contextualizing the Evidence in Lymphomas: ADCs and Bispecific Antibodies in HL, FL, and DLBCL
- John P. Leonard, MD
  Peer
- Matthew J. Matasar, MD
  Peer
- Alex Herrera, MD
  Peer
- Kami Maddocks, MD
  Peer
- Alison J. Moskowitz, MD
  Peer
- Sarah Rutherford, MD
  Peer
1.00 credits 9 episodes
Patient Selection for ADCs in First-Line DLBCL
MinuteCE®
Patient Selection for ADCs in First-Line DLBCL
- John P. Leonard, MD
  Peer
- Sarah Rutherford, MD
  Peer
1.00 program credits
Late-Stage Bispecifics and ADCs in DLBCL
MinuteCE®
Late-Stage Bispecifics and ADCs in DLBCL
- Sarah Rutherford, MD
  Peer
- John P. Leonard, MD
  Peer
1.00 program credits
Current Standards and Future Opportunities for ADCs in Advanced/Metastatic Triple-Negative Breast Cancer
CME/CE
Current Standards and Future Opportunities for ADCs in Advanced/Metastatic Triple-Negative Breast Cancer
- William J. Gradishar, MD
  Peer
- Javier Cortes, MD, PhD
  Peer
- Hope S. Rugo, MD, FASCO
  Peer
Current and Emerging Roles of Immunotherapy and ADCs for Patients with Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer
CME/CE
Current and Emerging Roles of Immunotherapy and ADCs for Patients with Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer
- Mamta Parikh, MD, MS
  Peer
- Daniel P. Petrylak, MD
  Peer
Utilization and Management of Antibody-Drug Conjugates in Metastatic Breast Cancer: The Relationship Between ADCs and HER2
CME/CE
Utilization and Management of Antibody-Drug Conjugates in Metastatic Breast Cancer: The Relationship Between ADCs and HER2
- William J. Gradishar, MD
  Peer
- Javier Cortes, MD, PhD
  Peer
- Hope S. Rugo, MD, FASCO
  Peer
Employing Immunotherapy and ADCs in Advanced Endometrial and Cervical Cancers: Current and Emerging Therapies
CME/CE
Employing Immunotherapy and ADCs in Advanced Endometrial and Cervical Cancers: Current and Emerging Therapies
- Robert L. Coleman, MD, FACOG, FACS
  Peer
- Susana Campos, MD, MPH
  Peer
- Domenica Lorusso, MD, PhD
  Peer
TROP2 ADCs for Metastatic NSCLC: Setting the Stage for Future Use
CME/CE
TROP2 ADCs for Metastatic NSCLC: Setting the Stage for Future Use
- Benjamin Levy, MD
  Peer
- Rebecca Heist, MD, MPH
  Peer
- Peter Bela Illei, MD
  Peer
HER2-Directed ADCs in Gastric Cancer
MinuteCE®
HER2-Directed ADCs in Gastric Cancer
- Jaffer Ajani, MD
  Peer
TROP2-Directed ADCs in Lung Cancer
MinuteCE®
TROP2-Directed ADCs in Lung Cancer
- Justin Gainor, MD
  Peer
HER3-Directed ADCs in Lung Cancer
MinuteCE®
HER3-Directed ADCs in Lung Cancer
- Justin Gainor, MD
  Peer
HER3-Directed ADCs in Breast Cancer
MinuteCE®
HER3-Directed ADCs in Breast Cancer
- Sara A. Hurvitz, MD, FACP
  Peer
TROP2-Directed ADCs in Breast Cancer
MinuteCE®
TROP2-Directed ADCs in Breast Cancer
- Sara A. Hurvitz, MD, FACP
  Peer